Epigenetics, the misunderstood science that could shed new light on ageing – The Guardian

A little over a decade ago, a clutch of scientific studies was published that seemed to show that survivors of atrocities or disasters such as the Holocaust and the Dutch famine of 1944-45 had passed on the biological scars of those traumatic experiences to their children.

The studies caused a sensation, earning their own BBC Horizon documentary and the cover of Time (I also wrote about them, for New Scientist) and no wonder. The mind-blowing implications were that DNA wasnt the only mode of biological inheritance, and that traits acquired by a person in their lifetime could be heritable. Since we receive our full complement of genes at conception and it remains essentially unchanged until our death, this information was thought to be transmitted via chemical tags on genes called epigenetic marks that dial those genes output up or down. The phenomenon, known as transgenerational epigenetic inheritance, caught the public imagination, in part because it seemed to release us from the tyranny of DNA. Genetic determinism was dead.

A decade on, the case for transgenerational epigenetic inheritance in humans has crumbled. Scientists know that it happens in plants, and weakly in some mammals. They cant rule it out in people, because its difficult to rule anything out in science, but there is no convincing evidence for it to date and no known physiological mechanism by which it could work. One well documented finding alone seems to present a towering obstacle to it: except in very rare genetic disorders, all epigenetic marks are erased from the genetic material of a human egg and sperm soon after their nuclei fuse during fertilisation. The [epigenetic] patterns are established anew in each generation, says geneticist Bernhard Horsthemke of the University of Duisburg-Essen in Germany.

Even at the time, sceptics pointed out that it was fiendishly difficult to disentangle the genetic, epigenetic and environmental contributions to inherited traits. For one thing, a person shares her mothers environment from the womb on, so that persons epigenome could come to resemble her mothers without any information being transmitted via the germline, or reproductive cells. In the past decade, the threads have become even more tangled, because it turns out that epigenetic marks are themselves largely under genetic control. Some genes influence the degree to which other genes are annotated and this shows up in twin studies, where certain epigenetic patterns have been found to be more similar in identical twins that in non-identical ones.

This has led researchers to think of the epigenome less as the language in which the environment commands the genes, and more as a way in which the genes adjust themselves to respond better to an unpredictable environment. Epigenetics is often presented as being in opposition to genetics, but actually the two things are intertwined, says Jonathan Mill, an epigeneticist at the University of Exeter. The relationship between them is still being worked out, but for geneticist Adrian Bird of the University of Edinburgh, the role of the environment in shaping the epigenome has been exaggerated. In fact, cells go to quite a lot of trouble to insulate themselves from environmental insult, he says.

Whatever that relationship turns out to be, the study of epigenetics seems to reinforce the case that its not nature versus nurture, but nature plus nurture (so genetic determinism is still dead). And whatever the contribution of the epigenome, it doesnt seem to translate across generations.

All the aforementioned researchers rue the fact that transgenerational epigenetic inheritance is still what most people think of when they hear the word epigenetics, because the past decade has also seen exciting advances in the field, in terms of the light it has shed on human health and disease. The marks that accumulate on somatic cells that is, all the bodys cells except the reproductive ones turn out to be very informative about these, and new technologies have made it easier to read them.

Different people define epigenetics differently, which is another reason why the field is misunderstood. Some define it as modifications to chromatin, the package that contains DNA inside the nuclei of human cells, while others include modifications to RNA. DNA is modified by the addition of chemical groups. Methylation, when a methyl group is added, is the form of DNA modification that has been studied most, but DNA can also be tagged with hydroxymethyl groups, and proteins in the chromatin complex can be modified too.

Researchers can generate genome-wide maps of DNA methylation and use these to track biological ageing, which as everyone knows is not the same as chronological ageing. The first such epigenetic clocks were established for blood, and showed strong associations with other measures of blood ageing such as blood pressure and lipid levels. But the epigenetic signature of ageing is different in different tissues, so these couldnt tell you much about, say, brain or liver. The past five years have seen the description of many more tissue-specific epigenetic clocks.

Mills group is working on a brain clock, for example, that he hopes will correlate with other indicators of ageing in the cortex. He has already identified what he believes to be an epigenetic signature of neurodegenerative disease. Were able to show robust differences in DNA methylation between individuals with and without dementia, that are very strongly related to the amount of pathology they have in their brains, Mill says. Its not yet possible to say whether those differences are a cause or consequence of the pathology, but they provide information about the mechanisms and genes that are disrupted in the disease process, that could guide the development of novel diagnostic tests and treatments. If a signal could be found in the blood, say, that correlated with the brain signal theyve detected, it could form the basis of a predictive blood test for dementia.

While Bird and others argue that the epigenome is predominantly under genetic control, some researchers are interested in the trace that certain environmental insults leave there. Smoking, for example, has a clear epigenetic signature. I could tell you quite accurately, based on their DNA methylation profile, if someone was a smoker or not, and probably how much they smoked and how long they had smoked for, says Mill.

James Flanagan of Imperial College London is among those who are exploiting this aspect of the epigenome to try to understand how lifestyle factors such as smoking, alcohol and obesity shape cancer risk. Indeed, cancer is the area where there is most excitement in terms of the clinical application of epigenetics. One idea, Flanagan says, is that once informed of their risk a person could make lifestyle adjustments to reduce it.

Drugs that remodel the epigenome have been used therapeutically in those already diagnosed with cancer, though they tend to have bad side-effects because their epigenetic impact is so broad. Other widely prescribed drugs that have few side-effects might turn out to work at least partly via the epigenome too. Based on the striking observation that breast cancer risk is more than halved in diabetes patients who have taken the diabetes drug metformin for a long time, Flanagans group is investigating whether this protective effect is mediated by altered epigenetic patterns.

Meanwhile, the US-based company Grail which has just been bought, controversially, by DNA sequencing giant Illumina has come up with a test for more than 50 cancers that detects altered methylation patterns in DNA circulating freely in the blood.

Based on publicly available data on its false-positive and false-negative rates, the Grail test looks very promising, says Tomasz K Wojdacz, who studies clinical epigenetics at the Pomeranian Medical University in Szczecin, Poland. But more data is needed and is being collected now in a major clinical trial in the NHS. The idea is that the test would be used to screen populations, identifying individuals at risk who would then be guided towards more classical diagnostic procedures such as tissue-specific biopsies. It could be a gamechanger in cancer, Wojdacz thinks, but it also raises ethical dilemmas, that will have to be addressed before it is rolled out. Imagine that someone got a positive result but further investigations revealed nothing, he says. You cant put that kind of psychological burden on a patient.

The jury is out on whether its possible to wind back the epigenetic clock. This question is the subject of serious inquiry, but many researchers worry that as a wave of epigenetic cosmetics hits the market, people are parting with their money on the basis of scientifically unsupported claims. Science has only scratched the surface of the epigenome, says Flanagan. The speed at which these things happen and the speed at which they might change back is not known. It might be the fate of every young science to be misunderstood. Thats still true of epidenetics, but it could about to change.

Until recently, sequencing the epigenome was a relatively slow and expensive affair. To identify all the methyl tags on the genome, for example, would require two distinct sequencing efforts and a chemical manipulation in between. In the past few years, however, it has become possible to sequence the genome and its methylation pattern simultaneously, halving the cost and doubling the speed.

Oxford Nanopore Technologies, the British company responsible for much of the tracking of the global spread of Covid-19 variants, which floated on the London Stock Exchange last week, offers such a technology. It works by pushing DNA through a nanoscale hole while current passes either side. DNA consists of four bases or letters A, C, G and T and because each one has a unique shape in the nanopore it distorts the current in a unique and measurable way. A methylated base has its own distinctive shape, meaning it can be detected as a fifth letter.

The US firm Illumina, which leads the global DNA sequencing market, offers a different technique, and chemist Shankar Balasubramanian of the University of Cambridge has said that his company, Cambridge Epigenetix, will soon announce its own epigenetic sequencing technology one that could add a sixth letter in the form of hydroxymethyl tags.

Protein modifications still have to be sequenced separately, but some people include RNA modifications in their definition of epigenetics and at least some of these technologies can detect those too meaning they have the power to generate enormous amounts of new information about how our genetic material is modified in our lifetime. Thats why Ewan Birney who co-directs the European Bioinformatics Institute in Hinxton, Cambridgeshire, and who is a consultant to Oxford Nanopore, says that epigenetic sequencing stands poised to revolutionise science: Were opening up an entirely new world.

The rest is here:
Epigenetics, the misunderstood science that could shed new light on ageing - The Guardian

Barriers Prevent Diversity Within Genetics Workforce, But Some Programs Aim to Bolster Representation – GenomeWeb

NEW YORK The lack of diversity within the genetics and genomics workforce not only means that it does not reflect the population it servesbut could also undermine patient care, according to a roundtable discussion organized by the National Academies of Sciences, Engineering, and Medicine.

This lack of diversity is particularly stark among genetic counselors where 90 percent of the workforce is white. Having the workforce better reflect the population it aims to serve the most recent US Census has found that an increasing proportion of the US population identifies as belonging to a minority group will also lead to better patient access and care.

"Having a diverse workforce is not just a nice thing to do," Sylvia Mann, the genomics section supervisor at the Hawaii State Department of Health, said during the roundtable presentations. "There is evidence that having a diverse workforce and student body is really supportive of services to underserved communities."

But there are a number of barriers to increased diversity, including a lack of exposure to the field, few role models, and a lack of support, according to the NASEM roundtable held this week. There are, though, ways to address some of those issues, such as through pathway programs, mentorship, and better reimbursement and pay for genetics professionals.

"Representation matters, and we have to invest in changing the professional profile of those involved in the genomics workforce," Altovise Ewing, a senior science leader at Genentech, added during the roundtable.

The past year has led to an increased focus on issues of diversity, equity, inclusion, and justice across society following the death of George Floyd and subsequent protests. This has prompted organizations like the American Association for the Advancement of Science to look into how to make both itself and the sciences more diverse. Similarly, the US National Human Genome Research Instituterecently announced an initiative to "adopt diversity as an ethos," especially in light of the field's past ties to eugenics.

However, the field has also had to grapple with current signs of overt racism, including incidents that led to the resignation of the outgoing president of the American College of Medical Genetics and Genomicsand theeditor-in-chief of the Journal of the American Medical Association.

The lack of diversity also has effects on patients, according to Ewing, limiting the reach of the benefits gained from genetics and genomics.

Because the workforce is predominately white, most genetic and genomic research has focused on a white, European-ancestry population and on research questions of concern to that population. Recent studies, for instance, have estimated that nearly 80 percent of individualsin genome-wide association studies have been of European ancestry. Such studies, when brought into the clinic, lead to unequal treatment of patients because less is then known about disease-associated variants that may be more common among other ancestry populations, which then affects professional and practice guidelines.

"This translates into inequities in opportunities for patients and families to engage in precision care, preventative screening, and innovative research options that will potentially stop diseases such as cancer in its tracks," Ewing said.

A more diverse workforce may identify research questions of interest and importance to different communities as well as lead to better communication with a diverse patient population through shared experiences and culture.

Addressing barriers

There are many known barriers to healthcare careers, Mann noted, including, for instance, a lack of exposure to fields like genetic counseling, a lack of role models or poor advising, and financial constraints, among others. Admission requirements like shadowing a genetic counselor or great reliance on MCAT scorescan also be a hindrance.

There are, though, ongoing programs aimed at addressing some of these barriers.

Omar Abdul-Rahman, the director of genetic medicine at the Munroe-Meyer Institute at the University of Nebraska Medical Center, for instance, is reaching out to high school students with the UNMC High School Alliance program.

Through the program, about 50 students a year spend about two hours a day on campus where they take classes taught by faculty and also spend about one afternoon a week learning about different career paths. The Omaha public schools are about 36 percent white, 25 percent Black, 26 percent Asian, and 6.5 percent Hispanic or Latino, according to Abdul-Rahman.

"We really need to think about getting that early exposure and going as early as possible because the effects of structural racism really start very, very early in the elementary and high school years," Abdul-Rahman said.

At the same time, Barbara Harrison, a genetic counselor at Howard University College of Medicine, added that pipeline programs linking, for instance, graduate programs in genetic counseling to historically Black colleges and universities or other undergraduate institutions serving underrepresented groups could help reach qualified applicants. She noted that though HBCUs represent 3percent of degree-granting institutions in the US, in 2013 they represented 17 percent of the colleges that supplied the most African American applicants to medical school.

Mentorship programs, Harrison noted, can also help interested college students who are not as familiar with the academic system to navigate the application process and its associated costs.

She added that the Genetics Opportunity Learning Development & Empowerment Networkis focused on increasing the number of Black genetic counselors by both raising awareness about the field and mentoring prospective applicants.

Hawaii's Mann added that programs should also try to ensure they are a safe space for minority students once they do arrive. "We get horrific stories about training programs and experiences in clinical rotations, and things like that are just bad for our minority students," she said.

Part of creating a safe space is to have institutional policies on diversity, equity, inclusion, and justice. This, Mann noted, is more than having an online training module about diversity but involves committing to open communication so students can discuss problems as well as having clear and transparent responses to any issues.

Having diverse faculty also helps to create a safe space, she added, noting that these faculty members can then be the next training program leaders. The Western States Regional Genetics Network, for which Mann serves as the project director, has a Minority Genetic Professionals Network for students, trainees, and professionals. In addition to its mentoring program, it also offers leadership training.

Overall, according to the American Society for Human Genetics' Chazeman Jackson, a roundtable moderator, there is a "societal imperative to bring diversity into genetics and genomics services, [and] the workforce must reflect the world we aim to serve and empower patients with agency. And if that doesn't happen, then we reduce our reach, we stifle our advancements, and we impede inclusion."

Here is the original post:
Barriers Prevent Diversity Within Genetics Workforce, But Some Programs Aim to Bolster Representation - GenomeWeb

Outcomes4Me Partners with Invitae to Offer Genetic Testing to Breast Cancer Patients – Business Wire

BOSTON--(BUSINESS WIRE)--Outcomes4Me Inc., developer of a leading free mobile app and platform to navigate cancer treatment and care, today announced that it has partnered with Invitae Corporation (NYSE: NVTA), a leading medical genetics company, to expand education and access to genetic testing to breast cancer patients and survivors. The collaboration leverages the strengths of Invitae, which supplies clinical grade genetic testing, and Outcomes4Mes 360-degree, validated and evidence-based cancer support and treatment options via its free and easy-to-use app. Initially and currently available in the United States, patients can now receive genetic counseling through Invitaes partnership with Genome Medical, get testing, and upload their results within the Outcomes4Me app.

There is a misconception that genetic testing is only useful as a preventative tool prior to a cancer diagnosis. According to Outcomes4Me patient data, almost half of users (46 percent) who qualified for testing (based on NCCN Guidelines) did not receive testing or did not know if they had received testing. However, genetic testing can provide insights that can help inform and refine precision therapy use and clinical treatment trial enrollment. In addition, genetic testing results can be used to help prevent recurrence and reduce incidence of other inherited cancers.

A cancer diagnosis is often overwhelming for patients and their families. Outcomes4Me demystifies cancer by providing the most up-to-date and validated research, support, and treatment options, all grounded in science and data and curated according to the patients specific diagnosis. Outcomes4Me partners with the researchers, doctors, and academics that set the rigorous standards of cancer care for all treatment providers, including the National Comprehensive Care Network (NCCN), Vanderbilt-Ingram Cancer Center (VICC) and Massachusetts General Hospital (MGH). The collaboration with Invitae expands access to genetic testing, a vitally important tool in the patients cancer care arsenal.

Outcomes4Me is an indispensable platform for patients with breast cancer, giving them the personalized knowledge and access to timely new trials and targeted therapies that could lead to better health outcomes, said Ed Esplin, M.D., Ph.D., FACMG, FACP, Clinical Geneticist at Invitae. By providing access to our comprehensive genetic testing and counseling services, Outcomes4Me is adding a valuable resource that will empower patients to advance their knowledge, understanding, and therefore, self-advocacy during treatment and survivorship.

Unlike popular direct-to-consumer genetic testing services, which test for a few specific genetic variants for certain genes, Invitae provides state-of-the-art clinical grade next-generation sequencing-based (NGS) genetic testing that comprehensively analyses more than 80 genes, including all known mutations of the important BRCA1/BRCA2 genes. This comprehensive approach, combined with associated genetic counseling, not only provides insights for cancer patients, but also for family members who may be at risk.

Our collaboration with Invitae reinforces Outcomes4Mes mission to give patients back control, said Maya R. Said, Sc. D., Founder and CEO of Outcomes4Me. Because of this work with Invitae, our valued community now has rare direct access to a much-needed testing service. Outcomes4Me will proudly continue to democratize the best in cancer treatment, research, and support by removing barriers and bias in information flow.

The Outcomes4Me app is available free to users on both the App Store and Google Play.

About Invitae

Invitae Corporation (NYSE: NVTA) is a leading medical genetics company whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices. For more information, visit the company's website at http://www.invitae.com.

About Outcomes4Me

Outcomes4Me is on a mission to improve health outcomes by empowering patients with understandable, relevant and evidence-based information. Outcomes4Me has developed a platform for shared decision-making between patients and providers. The platform harnesses regulatory-grade, real-world data and patient experiences generating deeper insights and better outcomes to improve care and accelerate research. The Outcomes4Me mobile app enables cancer patients to make decisions and take control of their care based on information that is personalized to their specific condition, including finding treatment options, matching to clinical trials, and tracking and managing symptoms. Based in Boston, Massachusetts, Outcomes4Me, a woman-led company, comprises seasoned healthcare, oncology, pharmaceutical, consumer and technology veterans. For more information, visit http://www.outcomes4me.com.

Follow this link:
Outcomes4Me Partners with Invitae to Offer Genetic Testing to Breast Cancer Patients - Business Wire

Classical genetics and traditional breeding in cucumbers – hortidaily.com

Rapid progress has been made in classical genetics and traditional breeding in cucumber for various quantitative and qualitative traits which greatly benefited the development of superior varieties suitable for open field and protected cultivation. The different breeding methods like plant introductions, hybridizations, pedigree selection, recombination breeding, and marker-assisted selection have been employed successfully in developing superior varieties and F 1 hybrids.

The development of new varieties with earliness, high yield, and resistance to diseases (powdery mildew, downy mildew, and tolerance to the virus) through a selection of superior parental lines followed by hybridization and marker-assisted introgression of desired genes was a game-changer in cucumber breeding. The exploitation of gynoecious sex along with parthenocarpic traits in traditional breeding has created a revolution in cucumber cultivation throughout the world which enabled the adoption of cucumber crops by the farming communities on a large scale.

Molecular markers technology could be exploited to overcome the obstacle of traditional breeding by accelerating the breeding cycle and selection of desirable traits. The high-density genetic maps for various traits have been constructed in cucumber to detected quantitative traits loci (QTLs) for genetic enhancement in different market classes of cucumber. Therefore, this research highlights the concepts of genetic foundations for advancement made in cucumber breeding.

Read the complete research at http://www.researchgate.net.

Jat, Gograj & Behera, Tusar & Lata, Suman. (2021). Classical Genetics and Traditional Breeding in Cucumber (Cucumis sativus L.). 10.5772/intechopen.97593.

Excerpt from:
Classical genetics and traditional breeding in cucumbers - hortidaily.com

What Can Genetics Tell Us About the Molecular Features of a Bladder Cancer Tumor? – SurvivorNet

Genetic Testing and Bladder Cancer

Genes are the basic units of inheritance in all living organisms. They provide cells with the necessary information for normal functioning, but they can be altered by the same environmental factors that cause cancer to develop.

Genetic testing helps identify specific genes that have mutated or been altered in a way that causes normal cells to become cancerous. These results are used by healthcare providers to predict responses to various types of treatment and monitor the progress of the disease. Genetic testing can refer to both germline testing (mutations in cells without cancer ) and also somatic testing of a patients tumor (mutations in cells with cancer).

Genetic testing is one of the most important things we can counsel patients about, says Dr. Arjun Balar, medical oncologist and assistant professor of medicine at the Perlmutter Cancer Center at NYU Langone Health.

What genetic testing means is understanding in a comprehensive way all the genetic abnormalities that may be present in one patients cancer that may not be present in others.

When examining genetic changes within tumor cells, researchers look for two main things:

These genetic abnormalities are what researchers are beginning to use as biomarkers for predicting patient responses to different forms of treatment.

In some families, bladder cancer occurs at higher rates than in the general population. In these cases, careful examination of the genealogy may reveal specific mutations passed from parent to child that may lead a medical provider to suspect one of the hereditary forms of bladder cancer. Some germline mutations linked to bladder cancer include:

While its possible, inherited gene mutations arent as commonly associated with bladder cancer as they are with other types of cancer, such as breast and ovarian. Sometimes, bladder cancer may occur in families because of toxic chemical or environmental exposures.

There are certain factors that increase an individuals risk for developing bladder cancer even if no family history exists. These include smoking and exposure to specific chemicals over long periods of time.

There are also inherited genetic syndromes that may place an individual at greater risk for developing bladder cancer. These include:

If genetic testing reveals you lack certain genes mutated in bladder cancer, you may be less likely to respond to certain treatments. These include targeted therapies, immunotherapies and chemotherapy drugs.

Genetic testing is not the only factor that determines your response to certain treatments. Even if your bladder cancer has all the genetic mutations that predict response to certain treatments, it still may not respond to them, because genetics is only one factor in determining a treatments effectiveness.

To increase the likelihood of response, bladder cancer treatments need to be combined with interventions designed to help your immune system target and kill cancer cells.

Genetic testing may also inform some decisions you and your medical team make as part of your ongoing care. If you are planning additional treatment after surgery or radiation, genetic testing may help determine the most appropriate treatment to use.

Genetic testing may be beneficial for many people with cancer. However, no guidelines exist to determine who should get genetic testing and the type of testing that should be done.

When I counsel a patient whos now undergoing their first treatment for advanced bladder cancer, Ill often encourage them to undergo genetic testing, mainly because we may find a genetic marker that is present in their cancer that might help me direct them toward a specific clinical trial that involves a drug that is specific for their genetic mutation, explains Dr. Balar.

Dr. Balar also recommends genetic testing for any patient with stage II or greater cancer. I advocate for early testing to have that information available early on so that if its needed, that information is readily available to make treatment decisions.

If youve been diagnosed with bladder cancer, talk to your healthcare team about the benefits and limitations of genetic testing.

Learn more about SurvivorNet's rigorous medical review process.

Lindsay Modglin is a freelance writer. Read More

Genetic testing helps identify specific genes that have mutated or been altered in a way that causes normal cells to become cancerous. These results are used by healthcare providers to predict responses to various types of treatment and monitor the progress of the disease. Genetic testing can refer to both germline testing (mutations in cells without cancer ) and also somatic testing of a patients tumor (mutations in cells with cancer).

What genetic testing means is understanding in a comprehensive way all the genetic abnormalities that may be present in one patients cancer that may not be present in others.

When examining genetic changes within tumor cells, researchers look for two main things:

These genetic abnormalities are what researchers are beginning to use as biomarkers for predicting patient responses to different forms of treatment.

In some families, bladder cancer occurs at higher rates than in the general population. In these cases, careful examination of the genealogy may reveal specific mutations passed from parent to child that may lead a medical provider to suspect one of the hereditary forms of bladder cancer. Some germline mutations linked to bladder cancer include:

While its possible, inherited gene mutations arent as commonly associated with bladder cancer as they are with other types of cancer, such as breast and ovarian. Sometimes, bladder cancer may occur in families because of toxic chemical or environmental exposures.

There are certain factors that increase an individuals risk for developing bladder cancer even if no family history exists. These include smoking and exposure to specific chemicals over long periods of time.

There are also inherited genetic syndromes that may place an individual at greater risk for developing bladder cancer. These include:

If genetic testing reveals you lack certain genes mutated in bladder cancer, you may be less likely to respond to certain treatments. These include targeted therapies, immunotherapies and chemotherapy drugs.

Genetic testing is not the only factor that determines your response to certain treatments. Even if your bladder cancer has all the genetic mutations that predict response to certain treatments, it still may not respond to them, because genetics is only one factor in determining a treatments effectiveness.

To increase the likelihood of response, bladder cancer treatments need to be combined with interventions designed to help your immune system target and kill cancer cells.

Genetic testing may also inform some decisions you and your medical team make as part of your ongoing care. If you are planning additional treatment after surgery or radiation, genetic testing may help determine the most appropriate treatment to use.

Genetic testing may be beneficial for many people with cancer. However, no guidelines exist to determine who should get genetic testing and the type of testing that should be done.

When I counsel a patient whos now undergoing their first treatment for advanced bladder cancer, Ill often encourage them to undergo genetic testing, mainly because we may find a genetic marker that is present in their cancer that might help me direct them toward a specific clinical trial that involves a drug that is specific for their genetic mutation, explains Dr. Balar.

Dr. Balar also recommends genetic testing for any patient with stage II or greater cancer. I advocate for early testing to have that information available early on so that if its needed, that information is readily available to make treatment decisions.

If youve been diagnosed with bladder cancer, talk to your healthcare team about the benefits and limitations of genetic testing.

Learn more about SurvivorNet's rigorous medical review process.

Lindsay Modglin is a freelance writer. Read More

Original post:
What Can Genetics Tell Us About the Molecular Features of a Bladder Cancer Tumor? - SurvivorNet

CDC, ClinGen Partner to Develop Curated List of Important Variants for Use in NGS Genetic Testing – GenomeWeb

NEW YORK The Centers for Disease Control and Prevention said on Monday that its Genetic Testing Reference Materials Program (GeT-RM) has partnered with the Clinical Genome Resource (ClinGen) to develop a publicly available list of 546 curated clinically important variants in 84 genes for use in next-generation sequencing genetic testing.

By defining variants that are either major contributors to disease or difficult to detect, the list will serve as a resource for the design of comprehensive analytical validation studies, as well as the creation of computer-modulated or simulated reference materials for clinical genomic test development, the partners said.

Genetic testing has grown from the analysis of small sets of known pathogenetic variants in one or a few genes to the analysis of hundreds or thousands of genes simultaneously using NGS, they added. But it's difficult, or even impossible, to obtain DNA reference materials containing the full scope of variants and variant types needed to perform a comprehensive validation study. It can also be challenging for laboratories to maintain the expert knowledge to identify variants that are appropriately representative of the spectrum of disease for inclusion in validation studies.

The new variant list, they said, will help address these complexities.

The CDC and ClinGen first proposed the curated list in a paper published in August in the Journal of Molecular Diagnostics. The variant types include 346 SNVs, 104 deletions, 37 copy number variants, 25 duplications, 18 deletion-insertions, five inversions, four insertions, two complex rearrangements, three difficult-to-sequence regions, and two fusions. They were nominated for a variety of reasons, including being major contributors to disease, analytically difficult to detect, or inadvertently filtered out due to high allele frequency.

The authors also noted that the list of 84 genes include 29 of the 73 genes recommended by the American College of Medical Genetics and Genomics for reporting of incidental or secondary findings.

The ClinGen Allele Registry was used to standardize nomenclature for all nominated variants, and ClinVar Variation IDs and associated disorders were added where available. The Food and Drug Administration has also recognized ClinGen's curation process and its resulting classifications as a regulatory-grade variant database, and the curated variants are available via the National Center for Biotechnology Information's ClinVar database and ClinGen's Evidence Repository.

"This important novel approach will remove a critical bottleneck for test developers and may help harmonize test development and validation across laboratories," co-lead investigator Birgit Funke, VP of genomic health at Sema4, said in a statement.

Co-lead investigator and GeT-RM Director Lisa Kalman also noted that the partners have started a pilot project to demonstrate how the curated variants "could be used to create reference materials by in silico mutagenesis of NGS sequencing files. The pilot will examine whether the added variants can be detected by the clinical laboratories that generated the NGS files and demonstrate a general process that labs can use to develop electronic reference materials to fit their own needs."

GeT-RM and ClinGen will continue to add to the current variant list as needed, and are inviting input from the genetics community about the list and the processes used to generate it.

Visit link:
CDC, ClinGen Partner to Develop Curated List of Important Variants for Use in NGS Genetic Testing - GenomeWeb

Arrhythmia: Is It a Genetic Condition? – Healthline

You inherit a lot of things from your parents, including the color of your eyes and how tall you will be. But not every genetic trait is a good one.

An arrhythmia is one example of a genetic health condition. These can also be called inherited or familial conditions.

While sudden cardiac death is extremely rare, affecting just 3 in every 100,000 people, a 2011 study found that about 70 percent of people under 40 who died from sudden cardiac issues had underlying heart arrhythmias that they inherited. This means that the issue with the hearts ability to beat regularly was passed on by one or both parents.

Sometimes, the issue is limited to a malfunction in the electrical signals in the heart, the American Heart Association says. But in about a third of cases, arrhythmias can develop because of structural issues, or the way the heart is formed.

Your heart operates using a complex electrical system that pulses through a detailed and delicate structure. Any time one of these electrical signals is off, or a part of the structure is damaged or formed incorrectly, it can create a host of issues.

Experts divide inherited heart arrhythmias into two categories:

All inherited heart arrhythmias are considered to be relatively rare conditions, but the most common types are:

Read on to learn about the main types of inherited heart arrhythmias.

Atrial fibrillation, also known as AFib or AF, is the most common type of heart arrhythmia overall. This condition involves the top chambers of the heart, which are known as the right and left atria.

In AFib, the right and left atria quiver and are not coordinated in pumping. This leads to compromised blood flow to the lower chambers of the heart, or the right and left ventricles.

AFib can cause blood to pool in the atria. This increases your chance of developing blood clots, which are potentially life threatening. A 2016 study estimated that up to a third of all strokes that occur in people ages 65 and older are due to AFib.

This condition can develop with age, but recent studies have found that up to 30 percent of people with AFib inherited it. According to MedlinePlus Genetics, several genes have been linked to the development of familial AFib:

Many of these genes provide instructions as your heart forms on how its electrical channels should be wired. If these channels arent wired correctly, then ions tiny particles with an electrical charge will have trouble passing signals through the muscles of your heart.

Brugada syndrome is another type of electrical issue in the heart that causes the ventricles to beat irregularly or too fast. When this happens, your heart cant pump blood out to the body effectively.

This can cause serious difficulties since many of your organs rely on a consistent and strong blood flow to work properly. In severe cases, Brugada syndrome can cause ventricular fibrillation, a potentially life threatening irregular heart rhythm.

A 2016 study showed that at least 23 genes are associated with this syndrome. The primary ones are:

This is a rare form of inherited arrhythmia. People with catecholaminergic polymorphic ventricular tachycardia (CPVT) will experience a very fast heart rhythm during physical activity, called ventricular tachycardia.

In CPVT, ventricular tachycardia usually happens during some form of exercise. Sometimes you can notice it before ventricular tachycardia occurs. You can do this by observing symptoms known as ventricular premature contractions (VPCs) during exercise.

With this type of genetic arrhythmia, the structure of the heart is usually unaffected. It typically appears in people 40 years and younger.

Specific genes linked to this condition are:

MedlinePlus Genetics says that RYR2 mutations account for about half of CPVT cases, while CASQ2 causes only about 5 percent. Both these genes are responsible for making proteins that help keep your heartbeat regular.

With this condition, the muscles that cause the heart to contract, or beat, take too long to recharge between pumps. This can upset the timing and regularity of your heartbeat, leading to other issues. While long QT syndrome can be caused by medications or other heart conditions, it can be inherited for many.

A 2016 study found that 15 genes are associated with this condition, but the most common are:

Most of the genes linked to familial arrhythmias are autosomal dominant, but some autosomal recessive disorders can cause long QT syndrome too. Genes KCNQ1 and KCNE1 are linked to rarer types of long QT syndrome called Jervell and Lange-Nielsen syndromes. In addition to inherited arrhythmias, people with these conditions also experience deafness.

This is an uncommon type of inherited arrhythmia. According to MedlinePlus Genetics, only about 70 cases of short QT syndrome have been diagnosed since it was recognized in 2000. Many more cases may exist, but they havent been diagnosed because this syndrome can occur without any symptoms.

With this condition, the heart muscle doesnt take long enough to charge between beats. This can cause no symptoms at all in some people. But in others, its the cause of sudden cardiac arrest or death.

Genes linked to this condition include:

With this rare condition, the heart has both structural and electrical issues. Electrical issues come in the form of a long QT interval, or the time it takes the heart to charge after each beat.

A long QT interval can lead to ventricular tachycardia, an often fatal arrhythmia. Ventricular tachycardia is the cause of death in about 80 percent of people with this syndrome.

Since this syndrome can also affect other parts of the body like the nervous system and immune system, many people with Timothy syndrome die during childhood. Its an autosomal dominant syndrome, meaning only one copy of an altered gene can lead to it. But because few people with Timothy syndrome survive into adulthood, its not usually passed from parent to child.

Instead, Timothy syndrome usually develops because of new mutations in the CACNA1C gene. This gene helps to manage the flow of calcium ions through heart muscles, affecting the regularity of your heartbeat.

Another issue with the hearts electrical system, Wolff-Parkinson-White syndrome occurs when an extra pathway for signals forms in the heart. This means that electrical signals can skip over the atrioventricular node, the part of the heart that helps control your heart rate.

When electrical signals skip over this node, it can cause your heart to beat extremely fast. This results in an arrhythmia called paroxysmal supraventricular tachycardia.

In some cases, this syndrome has been passed on through families. But most people who develop this condition have no family history. Also, for many people with this syndrome, the cause is unknown. A few cases are the result of mutations in the PRKAG2 gene.

This rare condition is primarily a structural issue. If you have this condition, a genetic mutation causes the muscle cells in your right ventricle the lower chamber of the heart to die. The condition mostly develops in people under age 35.

Arrhythmogenic right ventricular dysplasia usually develops with no symptoms at all. But it can still cause irregular heartbeats and even sudden death, especially during exercise. In later stages, this condition can also lead to heart failure.

Roughly half of all cases of arrhythmogenic right ventricular heart failure run in families. Autosomal dominant transmission from one parent is most common. But it can be passed on as an autosomal recessive gene from both parents, too. At least 13 genetic mutations have been connected to this disorder. PKP2 appears to be one of the most commonly affected genes.

Genes that cause this condition are responsible for forming desmosomes, or structures that connect muscle cells in the heart to each other. When these cells are not formed correctly, the cells that make up the muscles in your heart cant connect or communicate signals to one another.

Theres a lot of uncertainty around the cause of idiopathic ventricular fibrillation. Many people who are diagnosed with this condition have survived a cardiac arrest with ventricular fibrillation and no other obvious causes. A genetic cause has been proposed in a 2016 study, but research is ongoing.

Idiopathic means that a conditions origins are unknown. As genetic testing for other familial arrhythmias improves, it seems as though cases of idiopathic ventricular fibrillation are going down.

See the article here:
Arrhythmia: Is It a Genetic Condition? - Healthline

Genetics scientist: No new covid19 variant in Trinidad and Tobago – TT Newsday

NewsRia Chaitram2 Days AgoProfessor Christine Carrington -

A genetics scientist has dismissed claims that there were new covid19 variants in Trinidad and Tobago and by extension the rest of the Caribbean.

At the ministrys covid19 media conference on Saturday morning, professor of molecular genetics and virology at the University of the West Indies (UWI) campus in St Augustine, Christine Carrington said the claims of an undetermined strain stemmed from inaccurate reports on social media.

In September, reports coming out of Grenada suggested that there was an undetermined covid19 variant, which was attributable to its rise in cases in mid-August.

The claims said samples from Grenada as well as Barbados sent to the Caribbean Public Health Agency (CARPHA) for testing came back undetermined and further genome sequencing and analysis were needed.

Carrington said, I can assure that no undetermined variant was discovered among the samples from Grenada or Barbados when sent to Trinidad for home genome sequencing.

I am absolutely certain about this because it is my lab at UWI that does the sequencing and I report the results, myself, to CARPHA and to the Ministry of Health.

She described the claims as erroneous and said it came about because of a misinterpretation of the genome sequencing results.

Genome sequencing is like putting together a jigsaw puzzle, if you are able to extract enough pieces of the virus genetic information from a sample and, work out the position of the virus genome, then you can work out what lineage you are looking at, and whether it is a variant of concern.

Sometimes samples are not of sufficient quality to get enough pieces of that puzzle, to build enough of a picture to work out which lineage the virus belongs to. In those cases, to determine if it is a variant of concern, you cannot say yes or no because you do not have enough information, she explained.

As such, Carrington said, the low quality of the samples taken from Grenada and Barbados, was unable to show the lineage of the virus, which meant the results were undetermined and not that there was an undetermined variant.

She explained that home genome sequencing revealed the detailed structure of the virus and the only way to characterise new variants, while PCR testing was done to determine if the virus was present in a person, and they should not be confused.

When the matter was first detected and reported in September, the Pan-American Health Organization (PAHO) also dismissed the claim.

It said, Our specialists have confirmed with the laboratory involved that a result from the samples in Grenada could not be determined due to their low quality and not due to an undetermined variant.

Carrington added that in TT, the covid19 variants of concern were present were alpha, gamma and delta, in which gamma and delta were evidenced to be spread at community level and alpha was not.

The mu and lambda variants, she said were not detected in TT, but detected in other regional countries.

Read more here:
Genetics scientist: No new covid19 variant in Trinidad and Tobago - TT Newsday

Americans’ anxiety impacted by the ongoing pandemic, yet 1 in 5 say they won’t seek – EurekAlert

video:A new GeneSight Mental Health Monitor national survey finds many Americans are experiencing anxiety symptoms, but some wont seek treatment. view more

Credit: GeneSight Mental Health Monitor

Many Americans are experiencing anxiety symptoms as a result of the pandemic. Yet, one in five say they wont seek treatment for mental health conditions and others say they wont get help until these symptoms take a toll in their lives.

Nearly half (46%) of all respondents rated their anxiety symptoms as moderate to severe over the past six months, according to the GeneSight Mental Health Monitor from Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine.

Of those surveyed who are diagnosed with anxiety, the numbers are even worse 86% rated their anxiety symptoms as moderate to severe over the past six months. While the pandemic is only 18 months old, more than half of those diagnosed with anxiety say they lived with symptoms for years or decades before seeking treatment.

For those who havent sought treatment but are concerned they may be suffering from anxiety, only 36% are planning to seek treatment. When asked what it would take to get help for their anxiety, 47% said a debilitating panic attack. Additional reasons included not being able to leave their homes (34%), sleep issues (31%), an unshakeable feeling of dread (30%) and a negative impact to relationships (30%).

Imagine waiting until you lose your hearing to treat an ear infection. Patients who are experiencing anxiety symptoms shouldnt wait to seek treatment, said Robin Miller, Internist, MD, MHS, owner of Triune Integrative Medicine in Medford, Oregon. If you are afraid to go out, experiencing panic attacks, cant sleep, or your relationships are suffering, you dont have to live like this. You don't have to wait. You don't have to suffer for years. Help is out there and treatment can help.

The impact of COVID on anxiety

Many American adults expressed concern regarding how the pandemic has impacted their mental health:

Mental health conversation is shifting

Of those diagnosed with anxiety, nearly half said they would feel more comfortable talking about their mental health today than they would a year ago.

The pandemic appears to have made people willing to share their mental health struggles, said Mark Pollack, MD, chief medical officer for Mental Health at Myriad Genetics. Talking about mental health challenges is the first step towards getting treatment.

Mental health disorders should be treated

While more people appear to be willing to talk about their mental health, one out of five respondents still say they wont seek treatment. The top reasons for those who would NOT seek treatment for a mental challenge are:

Untreated anxiety can be associated with distressing and disabling panic attacks, intense worry, and disruption to your life, work and relationships, said Dr. Pollack. Like other medical conditions, individuals should seek evaluation and treatment as early as possible, to minimize the distress and dysfunction associated with these conditions.

Anna, a 32-year-old mother who was first diagnosed with anxiety in her early 20s, said that seeking treatment wasnt easy. She went through an extensive trial-and-error period with different medications and dosages.

Medication seems to work fast in my body, so after taking a medication that was supposed to help me, my anxiety would instead get worse I would have suicidal thoughts and be paralyzed with worry, said Anna. My doctor would increase the dosage or change medications, which would lead to horrible side effects.

Anna then took the GeneSight test, which analyzes how a patients genes may affect their outcomes with medications commonly prescribed to treat anxiety, depression, ADHD, and other psychiatric conditions.

After reviewing the results of my test, my psychiatrist reduced the dose by half, and it helped me. I honestly dont know if I would have taken another medication if it hadnt been for genetic testing, said Anna. Im glad I pursued treatment until I found a medication and dosage that worked for me. Now that Im not riddled with crippling anxiety, everything has gotten better. Im a better mom. Im more motivated, more outgoing and friendly.

For more information on how genetic testing can help inform clinicians on treatment of depression, anxiety, ADHD, and other psychiatric conditions, please visit GeneSight.com. To download graphics, a multimedia video and other information regarding the survey, please visit https://bit.ly/2Y4qGri.

About the GeneSight Mental Health Monitor

The GeneSight Mental Health Monitor is a nationwide survey of U.S. adults conducted by ACUPOLL Precision Research, Inc. in Aug.-Sept. 2021 among a statistically representative sample of adults age 21+, including a representative sample diagnosed with anxiety. The margin of error in survey results for the total base population at a 95% confidence interval is +/- 3%.

About the GeneSight Test

The GeneSight Psychotropic test from Myriad Genetics is the category-leading pharmacogenomic test for 61 medications commonly prescribed for depression, anxiety, ADHD, and other psychiatric conditions. The GeneSight test can help inform clinicians about how a patients genes may impact how they metabolize and/or respond to certain psychiatric medications. It has been given to more than 1.5 million patients by tens of thousands of clinicians to provide genetic information that is unique to each patient. The GeneSight test supplements other information considered by a clinician as part of a comprehensive medical assessment. Learn more at GeneSight.com.

About Myriad Genetics

Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and wellbeing for all, empowering individuals with vital genetic insights and enabling healthcare providers to better detect, treat and prevent disease. Myriad discovers and commercializes genetic tests that determine the risk of developing disease, assess the risk of disease progression, and guide treatment decisions across medical specialties where critical genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit the company's website: http://www.myriad.com.

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice CDx, Vectra, EndoPredict, Prequel, Foresight, GeneSight, riskScore and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries.

See the rest here:
Americans' anxiety impacted by the ongoing pandemic, yet 1 in 5 say they won't seek - EurekAlert

Research Fellow in Cell Biology job with UNIVERSITY OF SOUTHAMPTON | 267967 – Times Higher Education (THE)

DevelopmentalBiology

Location: Highfield CampusSalary: 31,406 to 38,587 per annumFull Time Fixed Term for 1 yearClosing Date: Wednesday 10 November 2021Interview Date: To be confirmedReference: 1409121BJ-R

You are invited to apply for a postdoctoral position to work in Dr. Salah Elias group at the School of Biological Sciences the University of Southampton, to study the mechanisms of oriented cell divisions (OCDs) during mammary epithelial morphogenesis. This position is available for 12 months in the first instance, tenable from January 2022. The post offers opportunities for flexible working, which can be agreed upon.

You will have a PhD* in a relevant subject area, with a strong cell biology component. A high level of competence in cell and molecular biology and high-resolution microscopy is required. Having previous experience in bioinformatics will be advantageous. You should be an enthusiastic and highly motivated scientist, a good team worker, and an excellent communicator.

Our group is interested in how regulation of cell division in the developing mammary gland influences mammary epithelial cell fate and dynamics, and the mechanisms of epithelial differentiation and architecture. We focus our efforts on addressing key questions of 1) how spindle orientation and cell polarity are controlled in dividing epithelial cells; 2) how these mechanisms influence epithelial morphogenesis; 3) and how their dysregulation leads to epithelial transformation and invasiveness. Specifically, this project utilizes a combination of molecular and cell biology, microscopic techniques, proteomics, and mass spectrometry to identify novel proteins that participate in OCDs. It offers excellent potential for preparing grant and fellowship proposals and developing new collaborations.

You will assume leadership on the project, including significant intellectual contribution, setting up collaborations, and involvement in making decisions about current and future research directions. You will work in a highly collaborative atmosphere supported by state-of-the-art research facilities that will provide a perfect environment to perform the studies.

*Applications for Research Fellow positions will be considered from candidates who are working towards or nearing completion of a relevant PhD qualification. The title of Research Fellow will be applied upon successful completion of the PhD. Prior to the qualification being awarded the title of Senior Research Assistant will be given.

For informal inquiries, please contact Dr. Salah Elias by email: S.K.Elias@soton.ac.uk

Equal Opportunities and Benefits

Biological Sciences holds an Athena SWAN Silver Award, demonstrating a commitment to equal opportunities and gender balance in the workplace.

We aim to be an equal opportunities employer and welcome applications from all sections of the community. Please note that applications from agencies will not be accepted.

The University of Southampton has a generous maternity policy** and onsite childcare facilities; employees are able to participate in the childcare vouchers scheme. Other benefits include state-of-the-art on-campus sports, arts and culture facilities, a full program of events, and a range of staff discounts.

**subject to qualifying criteria

Application Procedure

You should submit your completed online application form at http://www.jobs.soton.ac.uk. The application deadline will be midnight on the closing date stated above. Please include a covering letter and full CV in your application. References are requested along with your application, so please allow time for these to be received prior to the close date, to assist the department with shortlisting. If you need any assistance, please call Hannah Farrance (Recruitment Team) on +44 (0) 23 8059 2507. Please quote reference 1409121BJ-R on all correspondence.

Continue reading here:
Research Fellow in Cell Biology job with UNIVERSITY OF SOUTHAMPTON | 267967 - Times Higher Education (THE)